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Amyotrophic lateral sclerosis (ALS) is a progressive and fatal
degenerative disorder of motor neurons (MNs). Embryonic
stem cells (ESCs)/induced pluripotent stem cells (iPSCs) now
help us to understand the pathomechanisms of ALS via disease
modeling. Various methods to differentiate ESCs/iPSCs into
MNs by the addition of signaling molecules have been reported.
However, classical methods require multiple steps, and newer
simple methods using the transduction of transcription factors
run the risk of genomic integration of the vector genes. Hetero-
geneity of the expression levels of the transcription factors also
remains an issue.Herewedescribe a novel approach for differen-
tiating human and mouse ESCs/iPSCs into MNs using a single
Sendai virus vector encoding three transcription factors, LIM/
homeobox protein 3, neurogenin 2, and islet-1, which are inte-
gration free.This single-vectormethod, generatingHB9-positive
cells on day 2 from human iPSCs, increases the ratio of MNs to
neurons compared to the use of three separate Sendai virus vec-
tors. In addition, theMNs derived via thismethod from iPSCs of
ALS patients and model mice display disease phenotypes. This
simple approach signiﬁcantly reduces the efforts required to
generateMNs, and it provides a useful tool for diseasemodeling.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS), themost common and severe form
ofmotor neuron diseases (MNDs), causes progressivemuscle weakness
and leads to death within several years. Vast amounts of ﬁndings con-
cerning ALS have been reported, but the key mechanisms responsible
for the disease are still not fully understood, hampering treatment.
Consequently, the only FDA-approved drug, riluzole, was reported to
prolong patient lifespan by just a few months.1 The establishment of
induced pluripotent stem cells (iPSCs) offers a new approach to the
study of MNDs and the discovery of new drugs.2,3 In 2008, the ﬁrst
ALS patient iPSC-derivedmotor neurons (MNs)were generated.4 Since
then, many ALS iPSC studies have been reported,4–22 and this technol-
ogy is leading to new ﬁndings and therapeutic candidates for ALS.
MNs can be obtained from iPSCs, using signaling molecules such as
retinoic acid (RA) and Sonic hedgehog (Shh) (Table S1).4,5,12,23–29
These methods rely on developmental principles and require changing
the combinations of signalingmolecules atmultiple steps, which is why
somemethods requiremore than 4weeks to produceMNs. In contrast,
Hester et al. reported a rapid differentiation method using adenoviral
vectors that encode the transcription factors neurogenin 2 (Ngn2),
islet-1 (Isl1), and LIM/homeobox protein 3 (Lhx3).30 These three tran-
scription factorswere transduced into neural progenitor cells, andMNs
were obtained 11 days after the transduction. Son et al. reported that
mouse and human ﬁbroblasts were converted directly into MNs using
seven and eight transcription factors, respectively, encoded by retro-
virus vectors.31 In 2013, Mazzoni et al. generated doxycyclin-inducible
mouse embryonic stem cell lines to obtain MNs32 (Table S2). Methods
that rely on transcription factors are simple and rapid; but, whenweuse
them for research on MNDs, we have to consider the possibility of
genomic integration of the vector genes. Vector gene integration into
host genomes contains the risk of inﬂuencing the behaviors of the
transduced cells. Moreover, when we transduce several transcription
factors separately, the transduction ratio of each transcription factor
varies between the cells, and theheterogeneity of the cellsmay inﬂuence
the experimental results. Therefore, we decided to focus onSendai virus
(SeV) vectors33,34 (Table S3), which never integrate into host genomes
with highly efﬁcient transduction and expression levels of the trans-
gene(s), and we designed a single SeV vector that encodes Lhx3,
Ngn2, and Isl1 to produce more homogeneous MNs. Here we report
that MNs can be induced from ESCs/iPSCs using a single SeV vector
encoding a combination of transcription factors and that ALS
iPSC-derived MNs exhibit disease phenotypes.
RESULTS
Differentiation of Human iPSCs into MNs with Three Separate
SeV Vectors
First, we differentiated human iPSCs into MNs as described in Fig-
ure 1A. To detect MNs easily, we used HB9-EGFP knockin human
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iPSCs.35 On day 0, iPSCs were seeded on Matrigel-coated dishes and
the medium was changed from ESC medium to neurobasal medium
with N2 and B27 supplements. RA, smoothened agonist (SAG), and
neurotrophic factors (NTFs) also were added from day 0. For the
differentiation to MNs, three separate vectors, SeV18+Lhx3/
TS7DF (SeV-L), SeV18+Ngn2/TS7DF (SeV-N), and SeV18+Isl1/
TS7DF (SeV-I) were transduced into human iPSCs. To test the
transduction efﬁciency of the SeV vectors, we transduced SeV18+
EGFP/TS7DF (SeV-EGFP) into control iPSCs at the multiplicity
of infections (MOIs) of 1, 3, 10, 30, and 100. We observed
Figure 1. Differentiation of MNs with Three Separate Sendai Virus Vectors
(A) Outline shows the experimental procedure to generate MNs using SeV-Lhx3, SeV-Ngn2, and SeV-Isl1 from HB9-EGFP knockin human iPSCs. (B) Immunofluorescence
staining of iPSC-derived MNs for the MN markers HB9 and ChAT and for the neuronal markers Tuj1 and MAP2 is shown. Scale bars, 20 mm. (C) The percentages of HB9-
positive and Tuj1-positive cells per total cells were 7.3% ± 1.4% and 16.6% ± 4.8% on day 14, respectively. Error bars are SEM (n = 6). (D) The qPCR analysis of differentiated
cells on days 0 and 14 for MNmarkers (HB9 and ChAT) and neuronal marker (MAP2) is shown. Student’s t test was used for statistical comparison (*p < 0.05). Error bars are
SEM (n = 3).
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dose-dependent increases of EGFP-positive cells on day 2. However,
the ratios of EGFP-positive cells on day 4 compared to day 2
decreased at MOIs of 30–100 (Figure S1). Thus, we chose an
MOI of less than 30. On day 14, we observed HB9-positive neurons
and Tuj1-positive neurons, and 7.3% ± 1.4% and 16.6% ± 4.8% of
total cells were positive for HB9 and Tuj1, respectively (Figures
1B and 1C). The qPCR analysis showed increased expression levels
of HB9, ChAT, and MAP2 (Figure 1D). We also conﬁrmed via
immunocytochemistry and qPCR analysis that MNs can be gener-
ated from human ESCs with these SeV vectors (Figure S2).
To determine which combination of Lhx3, Ngn2, and Isl1 best
produces MNs from iPSCs, we transduced one to three of
SeV-L, SeV-N, and SeV-I into human iPSCs, and we evaluated
Tuj1 and HB9 expressions by immunocytochemistry. The combi-
nation of all three factors and the combination of SeV-L and
SeV-N produced both Tuj1- and HB9-positive neurons. The per-
centage of MNs per neurons was 43.9% ± 6.6% with all three
factors and 18.2% ± 1.1% with Lhx3 and Ngn2 (Figure S3). We,
therefore, decided to use all three factors for the differentiation
of MNs.
Differentiation to MNs by Lhx3, Ngn2, and Isl1 in a Single SeV
Vector and Time-Lapse Imaging
To increase the percentage of MNs per neurons, we designed a single
SeV vector encoding Lhx3, Ngn2, and Isl1 (SeV-L-N-I). Each trans-
gene was connected with the transcription termination (E), trinucle-
otide intergenic (I), and transcription restart sequence (S) of the Sen-
dai virus (EIS sequence). We examined the differentiation of MNs
using this vector (Figure 2A). On day 14, we observed both HB9-pos-
itive neurons and ChAT-positive neurons, and 6.2% ± 1.6% of the to-
tal cells were neurons and 5.3% ± 1.5% were MNs. The percentage of
MNs per neurons was 85.6% ± 1.7% (Figures 2B and 2C). We
conﬁrmed no MNs were obtained without SeV-L-N-I or with SeV-
EGFP vector only using the current protocol. Without RA and
SAG, HB9-positive cells were 48.5% ± 1.5% of neurons (Figures
S4A–S4C). We also analyzed populations other than neurons (Fig-
ure S4D). The qPCR analysis showed increased expression levels of
HB9, ChAT, and MAP2 (Figure 2D). By electrophysiological patch-
clamp analysis, we observed the action potentials of generated MNs
when co-cultured with primary astrocytes (Figure S4E). When MNs
were co-cultured with human myocytes differentiated from a human
myogenic cell line, Hu5/E18, the formation of neuromuscular
junctions was conﬁrmed by co-localization of HB9-EGFP-pos-
itive neurites with a-bungarotoxin-stained acetylcholine receptors
(Figure S4F).
To capture when HB9-positive cells emerge, we conducted time-
lapse imaging analysis using HB9-EGFP knockin iPSCs. Time-
lapse imaging of EGFP was started on day 1, and EGFP-positive
cells were observed on day 2. The number of EGFP-positive
cells gradually increased, but some of them disappeared as
time passed. On day 3, neuron-like morphology was observed
(Movie S1).
Differentiation to MNs by a Single SeV Vector Encoding Lhx3,
Ngn2, Isl1, and EGFP
Since the efﬁciency for the differentiation of neural lineage ap-
peared low based on the total number of cells, to investigate the
MN and neuron differentiation efﬁciency in SeV-infected cells,
we designed an SeV-L-N-I-EGFP vector, which could label SeV-in-
fected cells, and we transduced the three factors into iPSCs (Fig-
ure 3A). We found that >90% of SeV-L-N-I-EGFP-infected cells
had differentiated into MNs and neurons (Figures 3B and 3C).
The qPCR analysis showed increased expression levels of HB9,
ChAT, and MAP2 (Figure 3D). Then, to evaluate the terminal sub-
types of MNs along the rostrocaudal axis of the spinal cord, we
examined the expression of HOX genes by qPCR and
immunostaining.36 We observed increased mRNA expression of
HOXB4, HOXC6, and HOXC9 on day 14, but the expression
change of HOXC10 was not signiﬁcant. Immunostaining showed
that HOXC6-positive cells were about 60% of EGFP-positive cells
(Figure 4). To analyze the efﬁciency for the differentiation to
MNs from neural lineage cells, we transduced SeV-L-N-I-EGFP
after treatment with dorsomorphin and SB431542 for 4 or 7 days
(Figure 5). These results showed that the differentiation to MNs
from neural lineage cells increased the number of HB9-positive
cells compared to that from iPSCs.
SOD1-ALS and TDP-43-ALS MNs, Differentiated by a Single SeV
Vector Encoding Lhx3, Ngn2, and Isl1, Exhibit Disease-Specific
Phenotypes
To conﬁrm that our method is applicable to the research of MNDs,
we generated human iPSCs from the ﬁbroblasts of a familial ALS
patient with mutant superoxide dismutase 1 (SOD1 ALS) by trans-
ducing the four transcription factors Oct3/4, Sox2, Klf4, and c-Myc,
as previously reported3,7 (Table S4). The iPSCs were examined
immunocytochemically for the ESC markers SSEA4 and NANOG
(Figure S5A), and they were conﬁrmed to retain the SOD1 gene
mutation (Figure S5B). The generation of another familial ALS
patients (mutant TAR DNA-binding protein, 43 kDa [TDP-43]-
mediated ALS [TDP-43 ALS]), as well as control-derived iPSC
lines, was reported previously.7 When we differentiated human
ALS iPSCs into MNs using SeV-L-N-I (Figures S5C and S5D),
SOD1-ALS iPSC-derived neurons presented an accumulation of
misfolded SOD1 (Figures 6A and 6B), and TDP-43-ALS iPSC-
derived neurons exhibited cytosolic TDP-43 aggregation (Figures
6C and 6D). These cellular phenotypes were not speciﬁc to MNs
(Figures S5E and S5F).
Next, we generated iPSCs from embryonic ﬁbroblasts of ALS model
mice carryingmutant SOD137 or mutant TDP-4338 or from littermate
controls by transducing Oct3/4, Sox2, Klf4, and c-Myc, as previously
reported39,40 (Figure S6A; Table S5). We differentiated the iPSCs into
MNs to examine their phenotypes via immunocytochemistry (Figures
S6B and S6C). MNs derived from mouse SOD1-ALS iPSCs were
positive for misfolded SOD1, while those derived frommouse control
iPSCs were negative (Figure S6D).MNs derived frommouse TDP-43-
ALS iPSCs did not display the cytosolic aggregates of TDP-43
www.moleculartherapy.org
Molecular Therapy: Methods & Clinical Development Vol. 4 March 2017 117
(Figure S6E), which is consistent with a report on TDP-43-transgenic
mice.41
DISCUSSION
Along with the development of stem cell technology, stem cell-
derived MNs have been utilized for modeling MNDs in vitro. How-
ever, the heterogeneity of these MN populations presents a potential
issue for disease modeling and analysis. To obtain more homoge-
neous MNs, we used a single SeV vector that encodes three transcrip-
tion factors. SeV, known as murine parainﬂuenza virus type 1, is a
negative sense, single-stranded RNA virus of the family Paramyxovir-
idae. SeV vectors are cytoplasmic RNA vectors that do not integrate
Figure 2. Differentiation of MNs with a Single SeV Vector Encoding Lhx3, Ngn2, and Isl1
(A) Outline shows the experimental procedure to generate MNs from HB9-EGFP knockin human iPSCs using a single vector, SeV-Lhx3-Ngn2-Isl1 (SeV-L-N-I). (B)
Immunofluorescence staining of differentiated cells for HB9, Tuj1, MAP2, and ChAT is shown. Scale bars, 20 mm. (C) The percentages of HB9-positive and Tuj1-positive cells
per total cells on day 14 were 5.3% ± 1.5% and 6.2% ± 1.6%, respectively. Error bars are SEM (n = 3). (D) The qPCR analysis of the differentiated cells on days 0 and 14 for
HB9, ChAT, and MAP2 is shown. Student’s t test was used for statistical comparison (*p < 0.05). Error bars are SEM (n = 3).
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into host genomes.42 They can be transduced into both dividing
and non-dividing cells, and short-term exposure is enough for efﬁ-
cient transduction.43 SeV vectors can accommodate up to 5 kb of
insertion.
The present study demonstrated that the ratio of MNs to
neurons was higher when using a single SeV vector in com-
parison with three different SeV vectors for the transduction
of Lhx3, Ngn2, and Isl1. The differentiation of neural lineage
cells to MNs increases the percentage of HB9-positive cells per
total cells compared to that of iPSCs. However, this method
requires the dissociation and passage of cells and the change of
compounds. On the other hand, the direct addition of a single vec-
tor to iPSCs is a very simple method, and the rapid differentiation of
Figure 3. MN Differentiation Using a Single SeV Vector Encoding Lhx3, Ngn2, Isl1, and EGFP
(A) Outline shows the experimental procedure to generate MNs using SeV-L-N-I-EGFP from iPSCs. (B) Immunostaining for HB9, Tuj1, MAP2, and ChAT on day 14 is shown.
Scale bars, 20 mm. (C) Differentiation efficiency of MNs in SeV-infected cells is shown. The percentages of HB9-positive and Tuj1-positive cells per EGFP-positive cells were
92.8% ± 1.2% and 97.7% ± 1.2% on day 14, respectively. Error bars are SEM (n = 3). (D) The qPCR analysis for HB9, MAP2, and ChAT is shown. Student’s t test was used for
statistical comparison (*p < 0.05). Error bars are SEM (n = 3).
www.moleculartherapy.org
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MNs is beneﬁcial for research application. Moreover, immunocyto-
chemistry of MNs derived from control and ALS patient iPSCs
showed that MNs produced by this method are useful for research
on MNDs.
Figure 4. Characterization of MN Gene Expression Profile by a Single SeV Vector Encoding Lhx3, Ngn2, Isl1, and EGFP
(A) The qPCR analysis for HOXB4, HOXC6, HOXC9, and HOXC10 is shown. Student’s t test was used for statistical comparison (*p < 0.05). Error bars are SEM (n = 3). (B)
Immunostaining for HOXB4, HOXC6, HOXC9, and HOXC10 in MNs made by the SeV-L-N-I-EGFP vector is shown. Scale bars, 10 mm. (C) The percentage of HOX gene-
positive cells per EGFP-positive cells is shown. Error bars are SEM (n = 3).
Figure 5. Differentiation ofMNs fromNeural Lineage
Cells with a Single SeV Vector Encoding Lhx3, Ngn2,
Isl1, and EGFP
(A) Outline shows the experimental procedure to
generate MNs using SeV-L-N-I-EGFP from neural
lineage cells treated with dorsomorhpin and SB431542
for 4 days. (B) Immunostaining for HB9 and Tuj1 on
day 14 is shown. Scale bar, 20 mm. (C) Differentiation
efficiency of MNs in SeV-infected cells is shown. The
percentages of HB9-positive and Tuj1-positive cells
per EGFP-positive cells were 94.0% ± 1.3% and
97.6% ± 0.2% on day 14, respectively. Error bars
are SEM (n = 3). (D) The percentages of HB9-positive
and Tuj1-positive cells per total cells were 22.2% ±
0.4% and 23.1% ± 0.1% on day 14, respectively.
Error bars are SEM (n = 3). (E) Outline shows the
experimental procedure to generate MNs using SeV-
L-N-I-EGFP from neural lineage cells treated with
dorsomorhpin and SB431542 for 7 days. (F) Immuno-
staining for HB9 and Tuj1 on day 14 is shown. Scale
bar, 20 mm. (G) Differentiation efficiency to MNs of
SeV-infected cells is shown. The percentages of
HB9-positive and Tuj1-positive cells per EGFP-pos-
itive cells were 95.0% ± 1.1% and 97.3% ± 0.3% on
day 14, respectively. Error bars are SEM (n = 3). (H)
The percentages of HB9-positive and Tuj1-positive
cells per total cells were 31.6% ± 1.0% and 32.4% ±
0.8% on day 14, respectively. Error bars are SEM
(n = 3).
We also showed via time-lapse imaging
that HB9-EGFP-positive cells emerged within
2 days after the transduction of SeV-L-N-I
and that these cells extended neurites on day
3. Some of the cells gradually disappeared,
perhaps because the SeV vectors may have
had some cytotoxic effects or because we could
not change the medium during time-lapse
imaging.
There are still some challenges to be resolved.
First, the number of infecting vectors may
vary between individual cells. Second, the
SeV vectors should be easily removable from
the transduced cells after differentiation.
Removable SeV vectors are now being devel-
oped. In addition, the homogeneity of the
MNs needs to be further improved. Although further studies are
required to determine whether this method is applicable to other
types of neurons, we expect it will provide a new approach for
research on neurodegenerative diseases.
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In conclusion, we established a simple and useful method for differ-
entiating human iPSCs into MNs with a single SeV vector encoding
multiple transcription factors. This method will help to facilitate
stem cell-based research on MNDs.
MATERIALS AND METHODS
The generation and use of human iPSCs was approved by the Ethics
Committees of the respective departments, including Kyoto Univer-
sity. The procedures for generation of mouse iPSCs were performed
in accordance with the Kyoto University Animal Institutional Guide-
lines, and all experiments were approved by the Center for iPS Cell
Research and Application (CiRA) Animal Experiment Committee.
Derivation of Human Fibroblasts and Generation of iPSCs
Human ﬁbroblasts were obtained with written consent. The iPSCs
were generated according to a method previously described.7 After
selecting iPSC colonies, iPSCs were cultured and passaged on an
SNL feeder layer. The medium was primate embryonic stem cell
medium (ReproCELL) with 4 ng/mL basic ﬁbroblast growth factor
(Wako Chemicals) and 50 mg/mL penicillin and streptomycin.
The medium was changed every day and iPSCs were passaged about
once a week.
Figure 6. Phenotypes of SOD1-ALS and TDP-43-
ALS iPSC-Derived Neurons by a Single SeV Vector
Encoding Lhx3, Ngn2, and Isl1
(A) Immunostaining of misfolded SOD1 in control
and SOD1-ALS iPSC-derived neurons is shown.
Scale bar, 10 mm. (B) The percentages of misfolded
SOD1-positive neurons in control and SOD1-
ALS iPSC-derived neurons are shown. Student’s t test
was used for statistical comparison (*p < 0.05).
Error bars are SEM (n = 3). (C) Immunostaining
of TDP-43 in control and TDP-43-ALS iPSC-
derived neurons is shown. Scale bar, 10 mm. (D)
The percentages of TDP-43 aggregation-positive
neurons in control and TDP-43-ALS iPSC-derived
neurons are shown. Student’s t test was used for
statistical comparison (*p < 0.05). Error bars are
SEM (n = 3).
Derivation of Mouse Embryonic Fibroblasts
and Generation of iPSCs
Mouse embryonic ﬁbroblasts (MEFs) were
obtained from ALS model mice carrying
mutant SOD1 (G93A)37 or mutant TDP-43
(A315T)38 or from littermate controls. Four
reprogramming factors (Oct3/4, Sox2, Klf4,
and c-Myc) were introduced into the MEFs
using retroviral vectors as reported previ-
ously.39,40 Mouse iPSCs were cultured on
SNL feeder cells.
Genotyping
The human SOD1 gene was ampliﬁed
from genomic DNA by PCR and directly
sequenced using a 3500xL Genetic Analyzer (Applied
Biosystems).
Transduction Ratio by SeV Vectors into ESCs/iPSCs
To decide the transduction ratio by SeV vectors, SeV-EGFP (ID
Pharma) was transduced into control iPSCs. The iPSCs were treated
with collagenase type IV, trypsin, and knockout serum replacement
(CTK) dissociation solution (ReproCELL) for 2 min, dissociated to
single cells with Accumax (Innovative Cell Technologies), and trans-
ferred onto a 96-well plate coated with Matrigel (Becton Dickinson).
Cells were ﬁxed on day 2 and day 4. Images were captured by In Cell
Analyzer 6000 (GE Healthcare).
Differentiation of MNs from Human ESCs/iPSCs Using SeV
Vectors
ESCs/iPSCs were treated with CTK dissociation solution for 2 min
and feeder cells were removed with PBS. Then ESCs/iPSCs
were dissociated to single cells with Accumax, and they were trans-
ferred onto Matrigel-coated plates with MN medium containing a
1:1 mixture of Neurobasal medium (Thermo Fisher Scientiﬁc) and
DMEM/F12 (Thermo Fisher Scientiﬁc), supplemented with 0.5%
N2 (Thermo Fisher Scientiﬁc), 1% B27 (Thermo Fisher Scientiﬁc),
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1 mM retinoic acid (Sigma-Aldrich), 1 mM smoothened agonist
(Enzo Life Sciences), 10 ng/mL brain-derived neurotrophic factor
(BDNF; R&D Systems), 10 ng/mL glial cell-derived neurotrophic
factor (GDNF; R&D Systems), 10 ng/mL neurotrophin-3 (NT-3;
R&D Systems), and 10 mM Y-27632 (Nacalai Tesque). At the
same time, the ESCs/iPSCs were infected with SeV-L-N-I; SeV-
L-N-I-EGFP; or combinations of SeV-L, SeV-N, and SeV-I (ID
Pharma) on day 0. MOIs were 5 or 10. The transduction of SeV
vectors to human ESCs/iPSCs was conducted just once. The num-
ber of cells per well was 5.0  104 in 96-well plates and 1.0  106
in 12-well plates. The medium was changed to MN medium
without Y-27632 on day 1 and then changed every 3 days.
For phenotype assays, cells were treated with Accumax plus 10 mM
Y-27632 and transferred onto poly-L-lysine- and Matrigel-coated
glass dishes on day 7. For immunocytochemistry and qPCR analyses,
cells were assessed on day 14.
Differentiation of MNs from Mouse iPSCs Using an SeV Vector
The iPSCs were trypsinized into single cells and plated on Matrigel-
coated plates with MNmedium. At the same time, the iPSCs were in-
fected with SeV-L-N-I (ID Pharma) on day 0. TheMOI was 5 because
mouse iPSCs were damaged at an MOI of 10. The medium was
changed to MN medium without Y-27632 on day 1 and day 4. Cells
were assessed by immunocytochemistry on day 6.
RNA Extraction, cDNA Synthesis, and qPCR
RNA was isolated using RNeasy Mini Kit (QIAGEN) according to
the manufacturer’s instructions. The cDNA was synthesized using
the ReverTra Ace-a Kit (Toyobo). The qPCR was performed
with SYBR Premix Ex TaqII (Takara) by the StepOne Plus instru-
ment (Applied Biosystems). Primer sequences are described in
Table S6.
Co-culture of Human MNs with Human Myogenic Cells
The Hu5/E18 cell line was purchased from RIKEN BioResource
Center. Hu5/E18 cells were maintained and differentiated as pre-
viously reported.44 Cells were maintained in DMEM with high
glucose (Nacalai Tesque) containing 20% fetal bovine serum
(Gibco). Cells were differentiated into human myocytes in DMEM
containing 5 mg/mL holo-transferrin bovine (Sigma-Aldrich),
10 mg/mL insulin (bovine, Sigma-Aldrich), 10 nM sodium selenite
(Sigma-Aldrich), and 2% horse serum (Gibco) 7 days before SeV-
L-N-I transduction into iPSCs. The iPSCs were transduced with
SeV-L-N-I on day 0, dissociated with Accumax plus 10 mM
Y-27632, and then transferred onto Hu5/E18-cultured plates on
day 7. The medium was changed to MN medium. Cells were ﬁxed
with 4% paraformaldehyde (pH 7.4) for 30 min on day 14 and
assessed by immunocytochemistry.
Electrophysiological Recordings
Human iPSCs were transduced with SeV-L-N-I vector on day 0 and
plated onto astrocytes on day 7. Electrophysiological recording and
analysis were performed under microscopy in combination with dif-
ferential interference contrast (DIC) imaging on day 21, as previ-
ously described.7 During the electrophysiological recording, cells
were maintained at 30C and continuously superfused with oxygen-
ated Krebs-Ringer solution consisting of 125 mM NaCl, 2.5 mM
KCl, 2 mM CaCl2, 1 mM MgCl2, 26 mM NaHCO3, 1.25 mM
NaH2PO4, and 20 mM glucose. To examine whether iPSC-derived
MNs were functionally active, action potentials were measured in
current-clamp mode with a potassium chloride-based electrode so-
lution composed of 140 mM KCl, 2 mM MgCl2, 10 mM HEPES,
and 1 mM EGTA, adjusted to pH 7.4 with NaOH. For the
recording, an EPC 9 ampliﬁer (HEKA) was used, and the data
were analyzed with Patchmaster software (HEKA). Primary astro-
cytes were cultured from post-natal day (P)1 mouse in DMEM con-
taining 10% FBS.
Immunocytochemistry
Cells were ﬁxed with 4% paraformaldehyde (pH 7.4) for 30 min. The
cells were then permeabilized with 0.2% Triton X-100, and non-spe-
ciﬁc binding sites were blocked with Block Ace (Yukijirushi). Cells
were incubated with primary antibodies at 4C overnight and with
secondary antibodies at room temperature for 1 hr. Fluorescent im-
ages were captured using IN Cell Analyzer 6000, and the percentage
of MNs or neurons was calculated using IN Cell Developer Toolbox
v1.9 (GE Healthcare). For phenotype assays, images were acquired
by Delta Vision (GE Healthcare). The primary antibodies were as
follows: HB9 (Developmental Studies Hybridoma Bank [DSHB],
1:200), Tuj1 (Covance, 1:2,000), Tuj1 (Chemicon, 1:500) for Figures
6A and 6C, ChAT (Chemicon, 1:100), HOXB4 (DSHB, 1:50),
HOXC6 (Abcam, 1:200), HOXC9 (Abcam, 1:200), HOXC10 (Abcam,
1:2,000), misfolded SOD1 (MEDIMABS, B8H10, 1:200), misfolded
SOD1 (MEDIMABS, A5C3, 1:200), TDP-43 (Proteintech, 1:200), hu-
man Nanog (ReproCELL, 1:500), SSEA4 (Millipore, 1:200), SSEA1
(Chemicon, 1:1,000), Nestin (Millipore, 1:200), GFAP (Dako,
1:2,000), Iba1 (Wako Pure Chemicals Industries, 1:500), CNPase
(Cell Signaling Technology, 1:100), SOX17 (R&D Systems, 1:200),
and aSMA (Dako, 1:500). Tuj1 (Chemicon) was used to co-immu-
nostain with TDP-43.
Time-Lapse Imaging
For time-lapse imaging, 35-mm glass-bottom dishes (MatTek) were
coated with poly-L-lysine (Sigma-Aldrich) and Matrigel. Human
iPSCs transduced by SeV-L-N-I were plated on the dishes on day 0.
Themediumwas changed to FluoroBrite DMEM (Thermo Fisher Sci-
entiﬁc) supplemented with 0.5% N2, 1% B27, 1 mM retinoic acid,
1 mM smoothened agonist, 10 ng/mL BDNF, 10 ng/mL GDNF, and
10 ng/mL NT-3 on day 1. Time-lapse imaging was started 24 hr after
plating using BioStation IM-Q (Nikon). Images were captured every
30 min.
Statistical Analysis
All data are shown as mean ± SEM. Data were analyzed by Student’s
t test or one-way ANOVA followed by Dunnett’s post-hoc test;
p values < 0.05 were considered signiﬁcant. Statistical analyses were
performed with SPSS version 21 (IBM).
www.moleculartherapy.org
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